Kevin Krause Named President and CEO of ArrePath

BusinesswireNov 19 21:15

JMP Securities Maintains AN2 Therapeutics(ANTX.US) With Buy Rating, Maintains Target Price $5

Futu NewsNov 19 16:36 · Ratings

TD Cowen Initiates AN2 Therapeutics(ANTX.US) With Hold Rating

Futu NewsNov 19 16:36 · Ratings

Positive Outlook for AN2 Therapeutics: Buy Rating Justified by Strategic Pipeline Advancements and Strong Financial Health

TipRanksNov 19 13:35 · Ratings

AN2 Therapeutics Cut to Hold From Buy by TD Cowen

Dow JonesNov 18 22:05 · Ratings

AN2 Therapeutics Analyst Ratings

BenzingaNov 18 21:53 · Ratings